These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12962037)

  • 1. [Immunologic therapy for secondary and primary progressive multiple sclerosis].
    Ozawa K
    Nihon Rinsho; 2003 Aug; 61(8):1449-54. PubMed ID: 12962037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
    J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
    Kobelt G; Jönsson L; Miltenburger C; Jönsson B
    Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.
    Wu X; Dastidar P; Kuusisto H; Ukkonen M; Huhtala H; Elovaara I
    Acta Neurol Scand; 2005 Oct; 112(4):242-7. PubMed ID: 16146494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early treatment trials with interferon beta in multiple sclerosis.
    Panitch HS
    Mult Scler; 1995; 1 Suppl 1():S17-21. PubMed ID: 9345392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis].
    Cendrowski W
    Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels.
    Wu X; Kuusisto H; Dastidar P; Huhtala H; Nikkari ST; Ukkonen M; Höyhtyä M; Elovaara I
    Acta Neurol Scand; 2007 Jul; 116(1):43-8. PubMed ID: 17587254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH
    Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.
    Touchette DR; Durgin TL; Wanke LA; Goodkin DE
    Clin Ther; 2003 Feb; 25(2):611-34. PubMed ID: 12749517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis.
    Motamed MR; Najimi N; Fereshtehnejad SM
    Clin Neurol Neurosurg; 2007 May; 109(4):344-9. PubMed ID: 17300863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy in multiple sclerosis].
    Le Page E; Edan G
    Rev Prat; 2006 Jun; 56(12):1336-46. PubMed ID: 16948222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta-1a in primary progressive multiple sclerosis.
    Leary SM; Thompson AJ
    J Neurol Sci; 2003 Feb; 206(2):215-6. PubMed ID: 12559514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of drugs in secondary disease progression in patients with multiple sclerosis.
    Kappos L
    Mult Scler; 2004 Jun; 10 Suppl 1():S46-54; discussion S54-5. PubMed ID: 15218809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent therapeutic strategy for multiple sclerosis].
    Itoyama Y
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1214-7. PubMed ID: 12235841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.